Please login to the form below

Not currently logged in
Email:
Password:

emtricitabine

This page shows the latest emtricitabine news and features for those working in and with pharma, biotech and healthcare.

GSK’s says depot HIV injection works over three years

GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

Latest news

  • Janssen’s single tablet Symtuza gains NHS England funding  Janssen’s single tablet Symtuza gains NHS England funding 

    inhibitor (bPI) based regimens maintained similar virologic response rates and virologic rebound compared to continuing a regimen of boosted PI emtricitabine and TAF. ... Biktarvy is a combination of integrase inhibitor bictegravir with Gilead’s

  • ViiV chalks up another win for two-drug HIV regimen ViiV chalks up another win for two-drug HIV regimen

    fumarate and emtricitabine – two non-nucleoside RTIs – in previously-untreated HIV patients. ... Gilead’s new fixed-dose Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) triple.

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two

  • Gilead’s Biktarvy gets European approval, setting up battle with GSK Gilead’s Biktarvy gets European approval, setting up battle with GSK

    The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

  • The year of the blockbuster The year of the blockbuster

    Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

More from news
Approximately 6 fully matching, plus 78 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics